MX2010004097A - Complejos de los dominios de trpc y sestd1 y metodos y usos que implican los mismos. - Google Patents

Complejos de los dominios de trpc y sestd1 y metodos y usos que implican los mismos.

Info

Publication number
MX2010004097A
MX2010004097A MX2010004097A MX2010004097A MX2010004097A MX 2010004097 A MX2010004097 A MX 2010004097A MX 2010004097 A MX2010004097 A MX 2010004097A MX 2010004097 A MX2010004097 A MX 2010004097A MX 2010004097 A MX2010004097 A MX 2010004097A
Authority
MX
Mexico
Prior art keywords
domains
trpc
protein
sestd1
complexes
Prior art date
Application number
MX2010004097A
Other languages
English (en)
Inventor
Carsten Struebing
Susanne Miehe
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2010004097A publication Critical patent/MX2010004097A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Abstract

La presente invenci?n se refiere a un complejo, aislado que comprende una primera prote?na que comprende o consiste en un cl?sico canal de potencial de receptor transitorio (TRPC) o una variante funcionalmente activa del mismo y una segunda prote?na que comprende o consiste en el dominio de la primera espectrina (Spec 1) de SEC14 y los dominios 1 de espectrina (SESTD1), un sistema de prueba que comprende la primera prote?na y la segunda prote?na as? como los medios para detectar la interacci?n de la primera y la segunda prote?nas, un m?todo para cribar un modulador de TRPC usando el sistema y el uso del sistema de prueba para la identificaci?n de un modulador de TRPC.
MX2010004097A 2007-10-26 2008-10-14 Complejos de los dominios de trpc y sestd1 y metodos y usos que implican los mismos. MX2010004097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291300A EP2053059A1 (en) 2007-10-26 2007-10-26 Complexes of TRPC domains and SESTD1 domains and methods and uses involving the same
PCT/EP2008/008670 WO2009052971A1 (en) 2007-10-26 2008-10-14 Complexes of trpc domains and sestd1 domains and methods and uses involving the same

Publications (1)

Publication Number Publication Date
MX2010004097A true MX2010004097A (es) 2010-04-30

Family

ID=39232772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004097A MX2010004097A (es) 2007-10-26 2008-10-14 Complejos de los dominios de trpc y sestd1 y metodos y usos que implican los mismos.

Country Status (12)

Country Link
US (1) US20100330697A1 (es)
EP (2) EP2053059A1 (es)
JP (1) JP2011501757A (es)
KR (1) KR20100076992A (es)
CN (1) CN101848933A (es)
AR (1) AR069007A1 (es)
AU (1) AU2008315951A1 (es)
CA (1) CA2702508A1 (es)
IL (1) IL205218A0 (es)
MX (1) MX2010004097A (es)
TW (1) TW200934789A (es)
WO (1) WO2009052971A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103954770B (zh) * 2014-04-25 2015-09-30 江南大学 EVs-TRPC5在检测乳腺癌耐药程度中的应用
CN110777186A (zh) * 2019-10-29 2020-02-11 浙江树人学院（浙江树人大学） Trpc1对高糖培养的内皮细胞功能影响的实验方法
CN116891523A (zh) * 2023-05-24 2023-10-17 深圳晶蛋生物医药科技有限公司 一种trpm3截短体、包含其的细胞系及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI963989A (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
US7166701B2 (en) * 2000-03-24 2007-01-23 Merck Patent Gmbh Human survivin interacting protein 1 (SIP-1)
EP1709084A4 (en) * 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS

Also Published As

Publication number Publication date
CA2702508A1 (en) 2009-04-30
EP2053059A1 (en) 2009-04-29
EP2205628A1 (en) 2010-07-14
AR069007A1 (es) 2009-12-23
JP2011501757A (ja) 2011-01-13
IL205218A0 (en) 2010-11-30
TW200934789A (en) 2009-08-16
WO2009052971A1 (en) 2009-04-30
US20100330697A1 (en) 2010-12-30
CN101848933A (zh) 2010-09-29
KR20100076992A (ko) 2010-07-06
AU2008315951A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
WO2011047087A3 (en) Protein detection via nanoreporters
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
WO2008030513A3 (en) Method and system for providing an enhanced service-oriented architecture
WO2007101225A3 (en) Methods to identify inhibitors of the unfolded protein response
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
CL2010000720A1 (es) Método para la evaluar la respuesta a la inhibición de her en una muestra de paciente, que comprende detectar la proteina marcadora egf (div.sol.no. 1240-06).
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
DE60330126D1 (de) Substituierte pyridinone als modulatoren für p38 map kinase
CR9942A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
EP2101772A4 (en) NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS
MX2007002908A (es) Sondas inmovilizadas y metodos para detectar proteinas prionicas alteradas conformacionalmente.
EA200901646A1 (ru) Ингибиторы рецепторных тирозинкиназ и их применение
ATE476068T1 (de) Verfahren und vorrichtung zum umkonfigurieren eines gemeinsamen kanals
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
ATE328112T1 (de) Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
MX2010002994A (es) Dominios de fijacion del ligando de receptores nucleares en forma controlable y metodos que conllevan los mismos.
MX2010004097A (es) Complejos de los dominios de trpc y sestd1 y metodos y usos que implican los mismos.
SE0202157D0 (sv) Methods for identification of compounds modulating insulin resistance
ATE447628T1 (de) Einzelsequenzhybridisierungssonden
WO2010000874A3 (de) Markersequenzen für prostataentzündungserkrankungen, prostatakarzinom und deren verwendung